NM_006772.3:c.333delA
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_006772.3(SYNGAP1):c.333delA(p.Lys114SerfsTer20) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. P111P) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_006772.3 frameshift
Scores
Clinical Significance
Conservation
Publications
- complex neurodevelopmental disorderInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- intellectual disability, autosomal dominant 5Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
- autosomal dominant non-syndromic intellectual disabilityInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- SYNGAP1-related developmental and epileptic encephalopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- myoclonic-astatic epilepsyInheritance: Unknown Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| SYNGAP1 | NM_006772.3 | c.333delA | p.Lys114SerfsTer20 | frameshift_variant | Exon 4 of 19 | ENST00000646630.1 | NP_006763.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SYNGAP1 | ENST00000646630.1 | c.333delA | p.Lys114SerfsTer20 | frameshift_variant | Exon 4 of 19 | NM_006772.3 | ENSP00000496007.1 | |||
| SYNGAP1 | ENST00000644458.1 | c.333delA | p.Lys114SerfsTer20 | frameshift_variant | Exon 4 of 19 | ENSP00000495541.1 | ||||
| SYNGAP1 | ENST00000449372.7 | c.333delA | p.Lys114SerfsTer20 | frameshift_variant | Exon 4 of 18 | 5 | ENSP00000416519.4 | |||
| SYNGAP1 | ENST00000418600.7 | c.333delA | p.Lys114SerfsTer20 | frameshift_variant | Exon 4 of 19 | 5 | ENSP00000403636.3 | |||
| SYNGAP1 | ENST00000645250.1 | c.156delA | p.Lys55SerfsTer20 | frameshift_variant | Exon 2 of 17 | ENSP00000494861.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:5
- -
- -
Reported previously in the heterozygous state in a patient with epileptic encephalopathy, moderate intellectual disability, and autism spectrum disorder (Carvill et al., 2013); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 31395010, 25418537, 30541864, 23708187, 31440721) -
- -
- -
Intellectual disability, autosomal dominant 5 Pathogenic:4Other:1
- -
This sequence change creates a premature translational stop signal (p.Lys114Serfs*20) in the SYNGAP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SYNGAP1 are known to be pathogenic (PMID: 23161826, 23708187, 26989088). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with autism and/or intellectual disability (PMID: 25418537). ClinVar contains an entry for this variant (Variation ID: 430456). For these reasons, this variant has been classified as Pathogenic. -
_x000D_ Criteria applied: PVS1, PS4, PM2_SUP, PP3 -
Variant classified as Pathogenic and reported on 09-23-2014 by Fulgent Diagnostics . Assertions are reported exactly as they appear on the patient provided laboratory report. GenomeConnect does not attempt to reinterpret the variant. The IDDRC-CTSA National Brain Gene Registry (BGR) is a study funded by the U.S. National Center for Advancing Translational Sciences (NCATS) and includes 13 Intellectual and Developmental Disability Research Center (IDDRC) institutions. The study is led by Principal Investigator Dr. Philip Payne from Washington University. The BGR is a data commons of gene variants paired with subject clinical information. This database helps scientists learn more about genetic changes and their impact on the brain and behavior. Participation in the Brain Gene Registry requires participation in GenomeConnect. More information about the Brain Gene Registry can be found on the study website - https://braingeneregistry.wustl.edu/. -
The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000430456 /PMID: 23708187). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. -
Inborn genetic diseases Pathogenic:1
The c.333delA (p.K114Sfs*20) alteration, located in exon 4 (coding exon 4) of the SYNGAP1 gene, consists of a deletion of one nucleotide at position 333, causing a translational frameshift with a predicted alternate stop codon after 20 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant was reported in individuals with features consistent with SYNGAP1-related neurodevelopmental disorder; in at least one individual, it was determined to be de novo (Li, 2023; Wang, 2022; Kurtz-Nelson, 2020; Vlaskamp, 2019; Jimenez-Gomez, 2019; Truty, 2019; O'Roak, 2014; Carvill, 2013). Based on the available evidence, this alteration is classified as pathogenic. -
Infantile epilepsy syndrome Pathogenic:1
Submission from Simons Searchlight facilitated by GenomeConnect. Variant interpreted by the Simons Searchlight team most recently on 2018-04-27 and interpreted as Pathogenic. The reporting laboratory might also submit to ClinVar. This variant was identified in multiple probands enrolled in Simons Searchlight. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at